Cancer cells can further directly decrease T-cell-mediated antitumor immunity by overexpressing immune checkpoint ligands like PD-L1, the human endogenous retrovirus-H long terminal repeat-associating protein 2 (also known as B7-H7) [73] or by lowering MHC-I surface expression [76]. The gene discussed is HHLA2; the disease is cancer.